Vericel Corporation (VCEL)

Market Cap	2.10B
Revenue (ttm)	238.54M
Net Income (ttm)	2.98M
Shares Out	50.34M
EPS (ttm)	0.05
PE Ratio	803.09
Forward PE	139.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,581
Open	41.44
Previous Close	41.46
Day's Range	40.90 - 41.81
52-Week Range	37.39 - 63.00
Beta	1.32
Analysts	Strong Buy
Price Target	62.00 (+48.54%)
Earnings Date	Jul 31, 2025

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 1997
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL
• Website: https://www.vcel.com

Analyst Summary

According to 8 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price target is $62.0, which is an increase of 48.54% from the latest price.

Price Target

$62.0

(48.54% upside)

Analyst Consensus: Strong Buy